A Mesh Creation

About

About Flow Eighteen38

History

FlowEighteen38 is a new brand of the FairJourney Biologics group born to facilitate and accelerate antibody projects by delivering purified proteins and/or characterisation data of antibody panels and of lead candidates. This is complementary to our mammalian display and phage display discovery platforms and will further reduce risk for our partners by selecting the right antibody lead for cell line development and manufacturing

FairJourney Biologics and IONTAS combined capabilities in 2020 as a fee for service antibody discovery company. The combined operations allow a complete offering around antibody discovery. Uses fully validated naïve libraries with parallel immune approaches and the unrivalled mammalian display technology to optimise antibody discovery research. The team of more than 100 scientists, anchored in a high-profile network of advisors, has successfully completed more than 500 projects, with over 100 biotechnology and pharmaceutical companies.

View our technologies

One brand, three companies.

Our distinct and leading international brands joined forces to enable our current and future partners access to premium antibody discovery solutions, including the ability to leverage highly sought-after scientific know-how and expertise across our unified organization.

This combination creates a leading global antibody discovery CRO within our industry, offering unparalleled antibody services and technology platforms to global biopharmas , biotechs, universities, virtual companies and other innovative partnerships.

FairJourney Biologics

FairJourney Biologics is a leading biologics CRO, providing integrated services across antibody discovery, engineering and production to global biopharma. The Company’s significant expertise in phage display technology, combined with a diverse approach to generating both immune and naïve antibody libraries have contributed to a market leading 99%+ project success rate.

Visit website

IONTAS

IONTAS offers services for antibody discovery using Phage Display Technology and Mammalian Display. The innovative Mammalian Display platform enables full-length antibodies to be expressed in the context of a mammalian cell, thereby allowing selection based on function, stability, expression and developability.

Visit website

Flow Eighteen38

Flow Eighteen38 offers antibody production, from 96-well plates to deliver micrograms up to large scale, to deliver grams. Flow Eighteen38's services also comprise technologies for further functional and biophysical characterization including mass spectrometry, SPR, DLS, SLS, cIEF, CE-SDS, and chromatography methods. The services include antigen production, for use as immunogens and to generate new antibodies and reagents for research.

Visit website

Notable numbers
about our network

View our technologies

6
Antibodies in clinic
>500
Projects
5
Species
2885
Libraries Generated
>100
Customers
96
Employes
Capella Bioscience is happy with the partnership with FairJourney Biologics for being capital efficient. Such a big antibody discovery team gives us the peace of mind, knowing that they have…
— Steve Holmes
COO, Capella Bioscience
I strongly recommend FairJourney Biologics for the Service of sequencing mAb variable domains. They have performed an outstanding work solving all the technical problems in a reasonable period of time.…
— Dr. Jesús Salvador
Assistant Professor, National Center for Biotechnology, CNB-CSIC
I had the opportunity to work with FairJourney Biologics since last year and I am impressed by the skills and speed the different projects are delivered. I was personally involved…
— John Wijdenes
Mabdesign and CEO and consultant, AD&T consultancy
The experienced team of FairJourney Biologics worked with us in a very pleasant and collaborative way to develop several assay tools. They demonstrated to be very flexible and delivered on…
— Arnout Gerritsen
Associate Director, Assay and Bioanalytical Science at Genmab
FairJourney Biologics has demonstrated the capacity to deliver high quality antibody engineering services. The team is very experienced in phage display for the discovery of antibodies from rodent immune repertoires…
— Hans de Haard
CSO, arGEN-X
Many thanks to FairJourney Biologics for their invaluable help to design, develop and successfully qualify our potency ELISA assay. FJB even arranged on-site support for the transfer to our GMP…
— Paul da Silva Jardine
Co-founder and CSO, Staten Biotechnology B.V.
I was impressed by the remarkable efficacy, rapidity and smoothness of the service provided by FairJourney Biologics: 14 days between the hybridoma cells leaving our lab, and reception of the…
— Prof. Sophie Lucas
de Duve Institute Université catholique de Louvain Brussels, Belgium
View testimonials page

Our Story

Our organization was founded in 2012, with the goal of becoming the leader in antibody discovery by solving our clients needs. Since then, we have grown from strength to strength serving over 100 customers and completing over 500 projects worldwide. View some of our milestones by scrolling across.

  • 2012 Incorporation
    FairJourney Biologics and IONTAS incorporated
  • 2012
    1st Project and 1st Lab
  • 2013
    1st FTE contract Profitable
  • 2014
    1st Internal project
  • 05/2014
    VHH llama library
  • 06/2015
    1st Big pharma contract
  • 08/2015
    Human Library
  • 07/2016
    3200m2 New facilities
  • 08/2017
    Mammalian Display Patent
  • 11/2017
    Triple Vector patent
  • 2018
    1st Co-developed
    antibody licensed
  • 2019
    1st Licence on
    Mammalian Display
  • 05/2020
    IONTAS acquisition

Flow Eighteen38 launch

“We see Flow Eighteen38 as a significant milestone in combining knowledge across our organization into a new business unit. We look forward to expanding on our innovation in antibody discovery into the protein purification and characterization space, to offer faster and quality solutions for our current and future partners.”

This site uses cookies to provide you with a great user experience. By using our website, you accept our use of cookies.